EP4190802A4 - Nouveau peptide de pénétration cellulaire et utilisation associée - Google Patents

Nouveau peptide de pénétration cellulaire et utilisation associée Download PDF

Info

Publication number
EP4190802A4
EP4190802A4 EP21842399.4A EP21842399A EP4190802A4 EP 4190802 A4 EP4190802 A4 EP 4190802A4 EP 21842399 A EP21842399 A EP 21842399A EP 4190802 A4 EP4190802 A4 EP 4190802A4
Authority
EP
European Patent Office
Prior art keywords
penetrating peptide
cell penetrating
peptide
cell
penetrating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21842399.4A
Other languages
German (de)
English (en)
Other versions
EP4190802A1 (fr
Inventor
Quan Yuan
Shaojuan WANG
Sheng NIAN
Min Wei
Yali Zhang
Kai Wang
Yixin Chen
Tianying ZHANG
Shengxiang Ge
Ningshao Xia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yang Sheng Tang Co Ltd
Xiamen University
Original Assignee
Yang Sheng Tang Co Ltd
Xiamen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yang Sheng Tang Co Ltd, Xiamen University filed Critical Yang Sheng Tang Co Ltd
Publication of EP4190802A1 publication Critical patent/EP4190802A1/fr
Publication of EP4190802A4 publication Critical patent/EP4190802A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP21842399.4A 2020-07-17 2021-07-13 Nouveau peptide de pénétration cellulaire et utilisation associée Pending EP4190802A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010692443 2020-07-17
PCT/CN2021/106043 WO2022012539A1 (fr) 2020-07-17 2021-07-13 Nouveau peptide de pénétration cellulaire et utilisation associée

Publications (2)

Publication Number Publication Date
EP4190802A1 EP4190802A1 (fr) 2023-06-07
EP4190802A4 true EP4190802A4 (fr) 2024-04-03

Family

ID=79556027

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21842399.4A Pending EP4190802A4 (fr) 2020-07-17 2021-07-13 Nouveau peptide de pénétration cellulaire et utilisation associée

Country Status (5)

Country Link
US (1) US20230287086A1 (fr)
EP (1) EP4190802A4 (fr)
JP (1) JP7834294B2 (fr)
CN (1) CN115461358B (fr)
WO (1) WO2022012539A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113138276B (zh) 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN116554345A (zh) * 2023-02-06 2023-08-08 厦门大学深圳研究院 一种靶向kras穿膜抗体及其应用
CN116712554A (zh) * 2023-06-08 2023-09-08 江苏靶标生物医药研究所有限公司 一种穿膜肽l17e以非融合形式递送蛋白质分子的递送方法
CN116555197B (zh) * 2023-06-25 2023-09-01 中国科学院深圳先进技术研究院 一种沙门氏菌工程穿膜噬菌体及其构建方法与应用
CN117069799B (zh) * 2023-08-29 2025-07-08 百葵锐(深圳)生物科技有限公司 细胞穿膜肽及其应用
WO2025250808A1 (fr) * 2024-05-29 2025-12-04 The Brigham And Women’S Hospital, Inc. Compositions et méthodes d'administration anti-crispr

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034182A1 (fr) * 2007-09-14 2009-03-19 Institut Pasteur Polynucleotides permettant l'expression et la secretion d'un pseudo-virus recombine contenant des epitopes etrangers, production et utilisation de ces polynucleotides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518521A (ja) * 1998-06-20 2002-06-25 ワシントン・ユニバーシティ 医用画像解析、診断および治療のための膜透過性ペプチド錯体
CN101052414B (zh) * 2000-08-16 2012-10-10 塞尔德克斯医疗有限公司 具有增强的稳定性的免疫原性HBc嵌合体颗粒
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
CN101612405A (zh) * 2008-06-26 2009-12-30 中国人民解放军第三〇二医院 一种乙肝病毒前c-c基因疫苗的制备及应用
WO2010042743A2 (fr) * 2008-10-08 2010-04-15 Chimeros Inc. Multiplexes chimères, compositions et procédés permettant de les utiliser
CA2770075C (fr) * 2009-08-07 2021-08-24 Perrine Martin Composition pour le traitement d'une infection par le virus de l'hepatite b
US9403879B2 (en) * 2011-02-11 2016-08-02 The Trustees Of The University Of Pennsylvania Nucleic acid molecule encoding hepatitis B virus core protein and vaccine comprising the same
CN103243172B (zh) 2012-02-03 2015-02-04 中国科学院上海药物研究所 抗hbv的化合物的筛选方法
WO2014010971A1 (fr) * 2012-07-11 2014-01-16 주식회사 카엘젬백스 Peptide pénétrant dans une cellule, conjugué le comprenant et composition le comprenant
EP2986115A4 (fr) * 2013-02-06 2017-03-01 Academia Sinica Peptides antimicrobiens issus du domaine riche en arginine de la protéine c ur du virus de l'hépatite b
CN104710534B (zh) * 2015-02-12 2018-02-09 重庆医科大学 重组HBc融合蛋白
CN106480070B (zh) * 2015-08-25 2023-10-20 厦门大学 一种用于展示目的多肽的多肽载体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034182A1 (fr) * 2007-09-14 2009-03-19 Institut Pasteur Polynucleotides permettant l'expression et la secretion d'un pseudo-virus recombine contenant des epitopes etrangers, production et utilisation de ces polynucleotides

Also Published As

Publication number Publication date
WO2022012539A1 (fr) 2022-01-20
JP2023534054A (ja) 2023-08-07
US20230287086A1 (en) 2023-09-14
JP7834294B2 (ja) 2026-03-24
EP4190802A1 (fr) 2023-06-07
CN115461358A (zh) 2022-12-09
CN115461358B (zh) 2026-07-07

Similar Documents

Publication Publication Date Title
EP4209494C0 (fr) Composé de peptide court de proline à cycle modifié et son utilisation
EP4410818A4 (fr) Peptide possédant une activité anti-vieillissement, et son utilisation
IL281470A (en) Cellular reprogramming to reverse aging and promote organ and tissue regeneration
EP4349871A4 (fr) Polypeptide et son utilisation
EP4353249A4 (fr) Multi-agoniste et son utilisation
EP4253423A4 (fr) Protéine recombinante bispécifique et son utilisation
EP3712268A4 (fr) Cellule humaine transformée et son utilisation
EP4401752A4 (fr) Peptides antimicrobiens modifiés et leur utilisation
EP4433497A4 (fr) Polypeptides à domaine d et utilisations associées
EP3789396C0 (fr) Peptide synthétique sp2 et son utilisation
EP4365186A4 (fr) Peptide ayant une activité antidiabétique et son utilisation
EP4501943A4 (fr) Peptide ayant une activité antidiabétique, complexe peptidique et son utilisation
IL304607A (en) Compositions comprising pedf-derived short peptides (pdsp) and uses thereof
EP4453020A4 (fr) Polypeptides lilrb et leurs utilisations
EP3564255A4 (fr) Nouveau peptide à double fonction ayant une perméabilité cellulaire et une capacité de régénération de tissu osseux et utilisation de celui-ci
EP4434536A4 (fr) Peptide agrafé et son utilisation
EP4043076C0 (fr) Peptide cyclique possédant une activité inhibitrice de ctla-4 et application de celui-ci
EP4233916A4 (fr) Complexe, et son utilisation
EP4501344A4 (fr) Peptide présentant des activités anti-inflammatoires et antifibrotiques et son utilisation
EP4458961A4 (fr) Polypeptide isolé et son utilisation
EP4321527A4 (fr) Variant peptidique de pénétration cellulaire et son utilisation
EP4411027A4 (fr) Cellule électrolytique et dispositif électrolytique
EP4159744A4 (fr) Nouveau peptide anti-inflammatoire et utilisation associée
EP4373512A4 (fr) Polypeptides à feuillets alpha et leur utilisation
EP3565823C0 (fr) Peptides du s-arrestin et leur utilisation thérapeutique

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230131

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230628

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: C07K0014020000

Ipc: A61K0009060000

A4 Supplementary search report drawn up and despatched

Effective date: 20240306

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/22 20060101ALI20240229BHEP

Ipc: A61K 38/00 20060101ALI20240229BHEP

Ipc: A61K 47/42 20170101ALI20240229BHEP

Ipc: A61K 47/64 20170101ALI20240229BHEP

Ipc: A61K 9/06 20060101AFI20240229BHEP